Skip to content

Hereditary Tubulointerstitial Nephritis

Phenotypical and Genetic Characterization of Adult Hereditary Chronic Tubulointerstitial Renal Diseases

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01312727
Acronym
NTIH
Enrollment
225
Registered
2011-03-11
Start date
2010-11-30
Completion date
2016-07-31
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Failure, Gout, Nephritis, Interstitial, Renal Cysts

Keywords

Tubulointerstitial renal diseases, Hereditary renal diseases, Uromodulin, Renin gene

Brief summary

The aim of this study is to identify families with hereditary chronic tubulointerstitial renal diseases , characterize the phenotype and screen for mutations in known genesis (UMOD, REN, TCF2, NPHP1). Genome wide analysis will be performed in families without mutations identified.

Detailed description

* Inclusion of affected subjects with familial history of chronic renal failure, early gout ,renal cysts in several hospital in France * Characterization of the phenotype; dosage of the urinary uromodulin in all subjects * Collect DNA samples * Screen for UMO mutations first * Then for REN or TCF2 depending on the phenotype * Validate the use of the dosage of urinary uromodulin for the diagnosis of UMOD associated disease. * Identify new genes responsible for hereditary HTIN (Hereditary Tubulointerstitial Nephritis).

Interventions

OTHERBlood and urine sample collections

phenotype and genotype analysis, biological analysis

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years. * HTIN of unknown cause * Chronic renal failure defined by a eGFR (estimated Glomerular Filtration Rate) estimated according to MDRD (Modification of the Diet in Renal Disease) \< 60ml / min / 1,73m2. * At least two siblings affected by gout before 40 years or by chronic renal failure. * Affiliated or benefiting from a national insurance * Signature of the enlightened consent.

Exclusion criteria

* Endstage renal failure before the age of 18 years in all affected subjects of the family. * Microscopic or macroscopic persistent hematuria, or proteinuria \> 1gramme / 24hours. * Other potential cause of TIN (Tubulointerstitial Nephritis): pyelonephritis, drug toxicity. * High blood pressure known for more than 10 years before the discovery of the renal disease. * Major cardiovascular before the discovery of the renal disease. * Chronic auto-immune or infectious disease. * Polycystic kidney disease with increased of the size of the kidneys

Design outcomes

Primary

MeasureTime frameDescription
Genotype of HTINafter 18 monthsNumber of patients/families with mutations in known genes responsible for HTIN

Secondary

MeasureTime frame
Uromodulin dosage in urineat 18 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026